Biotech

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced the closing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share. As quoted in the press release: After deducting the underwriting discounts and …

UroGen Pharma (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced the closing of its public offering of 1,463,414 ordinary shares, at a public offering price of $41.00 per share.
As quoted in the press release:

After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $64 million. All ordinary shares sold in this offering were offered by the Company.

Jefferies LLC and Cowen and Company, LLC acted as joint book-running managers for the offering. Oppenheimer & Co. Inc. acted as lead manager for the offering. Ladenburg Thalmann & Co. Inc. and National Securities Corporation acted as co-managers for the offering.

Click here to read the full press release.

MARKETS

Markets
TSX18861.36-217.28
TSXV617.26-9.08
DOW30756.48-18.95
S&P 5003787.56+2.18
NASD11039.92+11.19
ASX6568.10-132.10

COMMODITIES

Commodities
Gold1800.66-6.21
Silver19.67-0.59
Copper3.58-0.13
Palladium1958.31+36.31
Platinum875.78-21.21
Oil107.52+1.76
Heating Oil3.94+0.11
Natural Gas5.83+0.41

DOWNLOAD FREE REPORTS

×